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The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the
favorable toxicity proﬁle associated with this agent make T-DM1 a potential therapeutic option for select patients with stage I
HER2-positive breast cancer. Moreover, T-DM1 is an established adjuvant treatment for patients with HER2-positive breast cancer
with the residual invasive disease after neoadjuvant therapy. Given that cardiotoxicity is the most signiﬁcant adverse event of
trastuzumab, which is a main molecular component of T-DM1, we conducted a sub-analysis of the ATEMPT trial to determine the
cardiac safety of adjuvant T-DM1. In this analysis, the incidence of grade 3–4 left ventricular systolic dysfunction (LVSD) in T-DM1
or trastuzumab plus paclitaxel arms were respectively 0.8 and 1.8%. In addition, three (0.8%) patients in the T-DM1 arm and six
(5.3%) patients in the adjuvant paclitaxel with trastuzumab (TH) arm experienced a signiﬁcant asymptomatic left ventricular
ejection fraction (LVEF) decline that per-protocol required holding T-DM1 or trastuzumab. All patients with available follow-up
data experienced full resolution of cardiac symptoms and LVEF normalization. Furthermore, we performed an exploratory analysis
to assess the relationship between age, baseline LVEF, and body mass index with cardiac outcomes. No signiﬁcant association
between these baseline characteristics and the incidence of signiﬁcant asymptomatic LVEF decline or symptomatic LVSD was
identiﬁed. The low incidence of signiﬁcant cardiac adverse events in this population during therapy with adjuvant T-DM1 suggests
that studies on the cost-effectiveness of cardiac monitoring during adjuvant therapy using anthracycline-free regimens are
needed.
Clinical Trial Registration: ClinicalTrials.gov, NCT01853748
npj Breast Cancer (2022)8:18 ; https://doi.org/10.1038/s41523-022-00385-2

INTRODUCTION
Ampliﬁcation or overexpression of the human epidermal growth
factor receptor 2 (HER2/neu) oncogene is present in ~15–20% of
early-stage breast cancers1,2, identifying an aggressive disease
subtype with a relatively high risk of recurrence in the absence of

HER2/neu-directed systemic therapy3. However, the development
of trastuzumab and a wide variety of additional biologic agents
targeting HER2/neu in the last two decades have provided great
clinical beneﬁts to this subgroup of patients, signiﬁcantly
improving long-term outcomes4.
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Fig. 1 CONSORT Flow Diagram of the study. Among 696 patients assessed for eligibility in the ATEMPT trial, 512 were randomized to receive
treatment with either adjuvant T-DM1 (n = 384, of which 383 received the intervention) or TH (n = 128, of which 114 received the
intervention).

While patients with stage I HER2-positive breast cancer were
either excluded from or underrepresented in pivotal trials that
established the survival beneﬁts of trastuzumab in combination
with poly-chemotherapy, retrospective data of untreated patients
showed that even these small HER2-positive breast cancers have
recurrence rates between 10–30%, justifying the need of adjuvant
treatment in this context5–8.
Efforts to evaluate less toxic adjuvant regimens for small HER2positive breast cancer have been conducted9, and based on the
excellent efﬁcacy outcomes in the adjuvant paclitaxel and
trastuzumab (APT) study10,11, adjuvant paclitaxel with trastuzumab
(TH) is currently considered a standard option for patients with
stage I HER2-positive breast cancer12,13. More recently, data from
the adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer
(ATEMPT) study demonstrated that, among patients with stage I
HER2-positive breast cancer, 1 year of adjuvant T-DM1 was
associated with a 3-year invasive disease-free survival rate of
97.8% (95% conﬁdence interval [CI]: 96.3–99.3%)14. Furthermore,
patient-reported outcomes indicated that patients treated with
T-DM1 had less neuropathy and alopecia, and better work
productivity compared with patients on TH, suggesting T-DM1
as an alternative treatment option for small HER2-positive tumors.
Adjuvant T-DM1 is also an established treatment for patients with
HER2-positive breast cancer not achieving pathological complete
response after neoadjuvant therapy15. There has consequently
been substantially more use of T-DM1 as adjuvant treatment, and
subsequently more risk of T-DM1-related adverse events.
Since cardiotoxicity is the most signiﬁcant adverse event of
trastuzumab, which is a main molecular component of T-DM1, the
objective of the current analysis is to determine the cardiac safety
of T-DM1 among patients on the ATEMPT study. As ATEMPT is the
only study in which patients with the early-stage disease received
1 year of T-DM1 without any other systemic chemotherapy, this is
an ideal opportunity to assess the cardiac safety of T-DM1
monotherapy.
npj Breast Cancer (2022) 18

RESULTS
Patient characteristics
From May 17, 2013 to December 13, 2016, 512 patients with stage
I HER2-positive breast cancer were enrolled in the ATEMPT trial
and 497 (383 T-DM1, 114 TH) started protocol therapy and were
included in this analysis (Fig. 1). Over 85% (424 of 497) of patients
had baseline left ventricular ejection fraction (LVEF) >55%. Race,
ethnicity, and sex were deﬁned by each patient, to demonstrate
the enrolled patient population. Median follow-up was 3.9 years,
corresponding to 1884 patient-years of follow-up. Baseline patient
characteristics did not differ between study arms (Table 1).
Changes in left ventricular ejection fraction
Overall, in both arms, the percentage of patients with a decline in
LVEF was low (Table 2). In the T-DM1 arm, the fraction of patients
with a decline in LVEF of 10–15% from baseline at 3 months,
6 months, 9 months, and 1 year, was 5%, 3%, 3%, and 3%,
respectively, and the fraction with an LVEF decline of ≥16% was
<1%, <1%, 1%, and <1% at the same timepoints. Similarly, in the
TH arm, 5%, 11%, 7%, and 3% of patients had a decline in LVEF of
10–15% from baseline at 3 months, 6 months, 9 months, and 1
year, respectively, and 0, 1%, 0, and 1% had a decline ≥16% from
baseline. In both arms, the median LVEF values were preserved
throughout treatment (Table 2). When restricting to patients that
completed one entire year of treatment, data regarding LVEF
changes was consistent with what was observed among the
overall study population (Supplementary Table 1).
Symptomatic left ventricular systolic dysfunction
Of 497 patients who started protocol therapy, 3 of 383 (0.8%; 95%
CI: 0.3–2.3) patients in the T-DM1 arm and 2 of 114 (1.8%; 95% CI:
0.5–6.2) patients in the TH arm developed grade 3 left ventricular
systolic dysfunction (LVSD). Among these ﬁve patients, only one
patient had comorbidities (diabetes mellitus and dyslipidemia)
and was receiving concomitant medications for cardiovascular
indications. None of these patients had hypertension at baseline.
Published in partnership with the Breast Cancer Research Foundation
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Table 1.

Baseline patient characteristics.

Characteristic

TH arm (n = 114)

T-DM1 arm (n = 383)

Median age (IQR)

56 [47, 62]

56 [49, 63]

Age group (years)
<50

41 (36%)

110 (29%)

50−59

35 (31%)

127 (33%)

60−69

30 (26%)

107 (28%)

8 (7%)

39 (10%)

≥70
Sex
Male
Female

1 (1%)

5 (1%)

113 (99%)

378 (99%)

93 (82%)

327 (85%)

Race
White
African American

7 (6%)

21 (5%)

Asian

4 (4%)

22 (6%)

10 (9%)

13 (3%)

Other
Ethnicity

1234567890():,;

Hispanic or Latino

1 (1%)

11 3%)

Non-Hispanic

97 (85%)

352 (92%)

Ethnicity not known

16 (14%)

20 (5%)

Baseline LVEF
50–55 (%)
>55 (%)
BMI
≤25

14 (12%)

59 (15%)

100 (88%)

324 (85%)

42 (37%)

161 (42%)

>25–30

33 (29%)

125 (33%)

>30

39 (34%)

97 (25%)

BMI body mass index, IQR intraquartile range, LVEF left ventricular ejection
fraction, T-DM1 trastuzumab emtansine, TH paclitaxel with trastuzumab.

With the exception of one patient who withdrew consent (and for
whom we do not have information), all others experienced full
resolution of cardiac symptoms and documented LVEF normalization. There was no grade 4 LVSD. Table 3 summarizes the
baseline clinical characteristics of these patients, the time of onset
of symptomatic cardiac dysfunction and its evolution, and the
clinical actions taken following the diagnosis.
Incidence of asymptomatic decrease in left ventricular
ejection fraction
Three (0.8%) patients in the T-DM1 arm and six (5.3%) patients in
the TH arm experienced a signiﬁcant asymptomatic LVEF decline
that per-protocol required trastuzumab hold. Three patients (two
in the TH arm and one in the T-DM1 arm) completed treatment
before cardiac decline was detected in their last scheduled cardiac
function assessment at 12 months. One patient spontaneously
recovered LVEF and no clinical action was taken. Another patient
was started on losartan and subsequently, her LVEF normalized.
Only one patient included in the TH arm discontinued protocol
therapy and because the patient withdrew consent, follow-up
information is not available. With regards to the other six patients
(two in the T-DM1 arm and four included in the TH arm), LVEF
spontaneously normalized without the need for any clinical action,
and protocol therapy was completed.
Risk factors for cardiac dysfunction
We performed an exploratory analysis to assess the relationship
between age, baseline LVEF, and body mass index with cardiac
outcomes. The percentage of patients with body mass index ≥30
Published in partnership with the Breast Cancer Research Foundation

(consistent with obese status) was 34% and 25% the TH and the
T-DM1 arms, respectively. No signiﬁcant association between
these baseline characteristics and the incidence of signiﬁcant
asymptomatic LVEF decline or symptomatic LVSD was identiﬁed
(Table 4). The cumulative probability of having a cardiac
dysfunction that ultimately led to T-DM1 interruption or
discontinuation at 6 and 12 months was 0.01 (95% CI: 0–0.01)
and 0.02 (95% CI: 0–0.04), respectively (Fig. 2). For the TH arm, the
cumulative probability of trastuzumab interruption or discontinuation due to a cardiac dysfunction was 0.03 (95% CI: 0–0.06) at
6 months and 0.08 (95% CI: 0.02–0.13) at 12 months.
DISCUSSION
The excellent outcomes observed in patients with early-stage
HER2-positive breast cancer treated with (neo)adjuvant HER2directed therapy have led to successful optimization of regimens
with fewer agents in patients with stage I HER2-positive breast
cancer10,11. More recently, because the outcomes seen in patients
treated with adjuvant T-DM1 in the ATEMPT trial and the
manageable toxicity proﬁle associated with this agent, it has
emerged as a potential alternative therapy to regimens such as TH
for select patients with stage I HER2-positive breast cancer14. In
view of this emerging utilization, as well as its established role as
adjuvant treatment for patients with stage II-III breast cancer with
residual disease after neoadjuvant therapy, it is of compelling
interest to characterize the cardiotoxic proﬁle of T-DM1.
The ATEMPT trial represents a unique opportunity to study
cardiac toxicity of T-DM1 as it is the only study that utilized 1 year
of T-DM1 without any additional systemic therapies (other than
endocrine agents) in the (neo)adjuvant setting. This trial found
that T-DM1 is associated with a low rate of grade 3 LVSD with only
three patients (0.8%) experiencing a grade 3 event, and two of
these patients fully recovered after receiving cardiac medications
(the third patient withdrew consent, and her cardiac outcomes are
unknown). In the TH arm, there were two patients with grade 3
LVSD (1.8%) and all had full recovery of LVEF. Moreover, all
patients with a signiﬁcant asymptomatic decline in LVEF who
would have required treatment interruption per-protocol (0.8% in
the T-DM1 and 5.3% in the TH arm) presented with subsequent
full recovery of LVEF and completed all planned therapy. Notably,
the percentage of patients experiencing a decline in LVEF of
10–15% from baseline never exceeded 5% in the T-DM1 arm,
whereas this percentage slightly increased in the TH arm between
the third and the 6th month (5 and 11%, respectively), and
subsequently dropped to 3% of the patients at 1 year. This trend
conﬁrms the reversible nature of trastuzumab-related cardiac
toxicity, with permanent events being very rare both with
trastuzumab and with T-DM1.
Risk factors associated with trastuzumab-related cardiac toxicity
include age, previous anthracycline exposure, coronary artery
disease, hypertension, diabetes, smoking, low-normal baseline
LVEF (50–55%), and obesity16,17. The population in the ATEMPT
trial is similar to the one included in the APT study; patients had a
median age of 56 years (10% of patients were 70 years or older),
and 15% had a low-normal baseline LVEF of ≤55%. We do not
have information about all patients’ history of hypertension,
diabetes mellitus, coronary artery disease, or smoking. Notably,
none of the three patients in the T-DM1 arm who developed
grade 3 LVSD had cardiovascular risk factors.
The incidence of signiﬁcant cardiac adverse events in the T-DM1
arm of the ATEMPT study is similar to what was observed in other
studies with different adjuvant regimens without anthracyclines,
including data from the APT study18 (trastuzumab plus paclitaxel),
the BCIRG 006 study19 (trastuzumab plus docetaxel and carboplatin), and the phase II study by Jones et al.20 with docetaxel and
cyclophosphamide with trastuzumab. In these studies, the
incidence of grade 3–4 LVSD were ≤0.5%. While the results
npj Breast Cancer (2022) 18
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Table 2.

Summary of LVEF at protocol-speciﬁed time points* and changes from baseline values.

TH arm (N = 114)

Baseline

3 months

6 months

9 months

1 year/EOT

LVEF reduction from baseline
<10%

-

94 (82%)

85 (75%)

86 (75%)

89 (78%)

10–15%

-

6 (5%)

12 (11%)

8 (7%)

3 (3%)

10–15% and below LLN

-

1 (1%)

2 (2%)

1 (1%)

1 (1%)

≥16%

-

0

1 (1%)

0

1 (1%)

Not performed
Not applicable

-

8 (7%)
6 (5%)

6 (5%)
10 (9%)

7 (6%)
13 (11%)

14 (12%)
7 (6%)

62.5 [60–65]

62 [60–65]

60 [59–65]

60 [59–65]

62 [60–65]

Baseline

3 months

6 months

9 months

1 year/EOT

LVEF level (%)
Median (IQR range)
T-DM1 arm (N = 383)
LVEF reduction from baseline
<10%

-

330 (86%)

320 (84%)

284 (74%)

256 (67%)

10–15%

-

19 (5%)

13 (3%)

10 (3%)

12 (3%)

10–15% and below LLN
≥16%

-

1 (0%)
1 (0%)

0
1 (0%)

0
2 (1%)

1 (0%)
1 (0%)

Not performed

-

20 (5%)

10 (3%)

21 (5%)

74 (19%)

Not applicable

-

13 (3%)

39 (10%)

66 (17%)

40 (10%)

63 [60–65]

62 [60–65]

63 [60–66]

63 [60–66]

63 [60–67]

LVEF level (%)
Median (IQR range)

EOT end of treatment, IQR intraquartile range, LLN lower limit of normal, LVEF left ventricular ejection fraction, T-DM1 trastuzumab emtansine, TH paclitaxel with
trastuzumab.
*Each timepoint uses a window of 6 weeks. If more than one cardiac assessment falls into each window, the worst assessment is used.

Table 3. Summary of baseline clinical characteristics and clinical evolution of patients with symptomatic cardiac dysfunction during the
ATEMPT study.
#ID

Clinical baseline
characteristics
Age

LVEF assessment overtime

Clinical actions after diagnosis of symptomatic cardiac dysfunction and
outcome

BMI

HTN

DM

BL

3m

6m

9m

End of Tx

Dose hold

Was Tx resumed?

Medication started

Did LEVF normalizec?

T-DM1 arm
12
274

51
61

26.4
21.2

No
No

No
No

60
55

65
40b

55
NA

30b
NA

30
40

Yes
Yes

No
No

ACEi and beta-blocker
ACEi

Yes
NR

427

65

28.6

No

No

76

58b

63

57

57

Yes

No

no

Yes

58

21.5

No

No

70

65

58b

79

65

Yes

Yes

no

Yes

48

39.8

No

Yes

60

60

45b

NA

45

Yes

No

Beta-blocker

Yes

TH arm
116
a

299

ACEi angiotensin-converting enzyme inhibitor, BL baseline, BMI body mass index, DM diabetes mellitus, HTN hypertension, LVEF left ventricular ejection
fraction, M months, NR not reported, T-DM1 trastuzumab emtansine, TH paclitaxel with trastuzumab, Tx treatment.
a
At the time of study start, patient #299 was on metformin and rosuvastatin due to diabetes mellitus and hypercholesterolemia.
b
Time point when therapy was interrupted.
c
Among all cases in which LVEF normalized, the symptoms also resolved.

presented in the current analysis are based on a median follow-up
of 3.9 years, it is unlikely that these rates will increase since late
cardiac toxicity from HER2-targeting agents is rare21,22. In addition,
these rates are favorable compared to grade 3–4 LVSD or
symptomatic heart failure (HF) rates (2.3%) reported in a pooled
analysis of pivotal adjuvant clinical trials using regimens containing anthracyclines16. While the incidence of grade 3 LVSD (1.8%) in
the TH arm is higher than in the APT study, this could be due to
chance given the small number of patients in this arm.
Our study has several limitations. First, data on baseline cardiac
risk factors were not uniformly collected in this trial. For instance,
we did not collect speciﬁc information on the history of
npj Breast Cancer (2022) 18

hypertension, diabetes mellitus, and coronary artery disease at
baseline. In this study, we retrospectively collected this information for patients who developed grade 3–4 LVSD and asymptomatic LVEF decline that led to treatment interruption or
discontinuation. Second, LVEF quantiﬁcations were not performed
according to a prespeciﬁed protocol, and testing was conducted
per local institutional standards without a central read performed.
Third, patients with comorbidities associated with high risk for
developing trastuzumab-associated cardiotoxicity, including a
history of HF, were excluded from this study, thus these results
cannot be generalized to a population of patients with relevant
cardiac risk factors. Additionally, the population of patients
Published in partnership with the Breast Cancer Research Foundation

R. Barroso-Sousa et al.

5
Table 4.

Cross-tabulation of baseline characteristics and LVSD/asymptomatic LVEF decline on and off treatment.

LVEF reduction from
baseline
TH arm

Total number of
patients
114

No cardiac toxicity Symptomatic congestive heart failure or
asymptomatic LVEF decline
106
8

RR (95%)

P

0.42

Age at study entry (years)
<50

41 (36%)

37 (35%)

4 (50%)

Reference

≥50

73 (64%)

69 (65%)

4 (50%)

0.56 (0.15-2.13)

≤55

14 (12%)

13 (12%)

1 (12%)

1.02 (0.14–7.69)

>55

100 (88%)

93 (88%)

7 (88%)

Reference

42 (37%)
72 (63%)

39 (37%)
67 (63%)

3 (38%)
5 (62%)

Reference
0.97 (0.24–3.86)

0.95

383

377

6
0.58

Baseline LVEF (%)
0.92

BMI
≤25
>25
T-DM1 arm
Age at study entry (years)
<50

110 (29%)

109 (29%)

1 (17%)

Reference

≥50

273 (71%)

268 (71%)

5 (83%)

2.01 (0.24–17.05)

Baseline LVEF (%)
≤55

59 (15%)

57 (15%)

2 (33%)

2.74 (0.51–14.65) 0.28

>55
BMI

324 (85%)

320 (85%)

4 (67%)

Reference

≤25

161 (42%)

158 (42%)

3 (50%)

Reference

>25

222 (58%)

219 (58%)

3 (50%)

0.73 (0.15–3.55)

0.70

BMI body mass index, LVEF left ventricular ejection fraction, LVSD left ventricular systolic dysfunction, RR relative risk, T-DM1 trastuzumab emtansine, TH
paclitaxel with trastuzumab.

enrolled in ATEMPT was enriched in white patients, patients
younger than 60 years old and with a baseline EF >55%, thus
representing a selected population compared to that treated in
everyday practice. Lastly, the medical management of decreases
in LVEF during therapy was per physician discretion; however, all
patients for whom we have information had a full cardiac
recovery.
In conclusion, we found in this population of patients with small
HER2-positive breast cancers that during treatment with adjuvant
T-DM1 the incidence of grade 3–4 LVSD (symptomatic HF) and
signiﬁcant asymptomatic decreases in LVEF were low: both rates
were 0.8%. Such low incidence raises the question of whether
close serial LVEF monitoring should be performed in all patients or
be reserved for patients considered at a higher risk of developing
cardiotoxicity and those with symptomatic HF or other cardiac
symptoms. Finally, we look forward to seeing the results of
ongoing investigations of reduced frequency of LVEF monitoring
during anthracycline-free regimens.
METHODS
Study design and patient population
Fig. 2 Kaplan–Meier estimate of the cumulative probability of a
cardiotoxicity# event during the treatment period. Probability of
cardiotoxicity by 6 months: TH: 0.03 (95% CI: 0–0.06); T-DM1: 0.01
(95% CI: 0–0.01). Probability of cardiotoxicity by 12 months: TH: 0.08
(95% CI: 0.02–0.13); T-DM1: 0.02 (95% CI: 0–0.04). Cardiotoxicity here
is deﬁned as grade 3–4 left ventricle systolic dysfunction (LVSD) or
signiﬁcant asymptomatic left ventricular ejection fraction (LVEF)
decline (decrease in the ejection fraction of 10–15 percentage
points from baseline with an ejection fraction at least 1 percentage
point below the lower limit of normal, or a decrease of 16 or more
percentage points from baseline). T-DM1 trastuzumab emtansine,
TH paclitaxel with trastuzumab. *15 patients censored at time 0 due
to having only baseline cardiac assessments (ten in T-DM1 arm and
ﬁve in the TH arm.
Published in partnership with the Breast Cancer Research Foundation

This was a randomized phase II study across 24 centers in the United States
investigating the regimen of weekly paclitaxel with trastuzumab or T-DM1
in patients with stage I HER2-positive breast cancer (NCT01853748). The
study was approved by the institutional review board at each site. Written
informed consent was obtained from each patient. Patients were required
to be ≥18 years of age and have an Eastern Cooperative Oncology Group
performance status ≤1, LVEF ≥50%, within 90 days of their most recent
breast surgery, and no history of prior breast cancer. Patients were
stratiﬁed by age (<55 vs. ≥55 years), planned use of radiation therapy (yes/
no), and planned use of endocrine therapy (yes/no), and randomized in a
3:1 ratio to receive T-DM1 or TH, respectively. Adjuvant radiation therapy
and hormonal therapy (when appropriate) could be initiated after 12 weeks
of T-DM1 (Arm 1) or after the conclusion of paclitaxel therapy (Arm 2).
Patients in the T-DM1 arm received T-DM1 3.6 mg/kg intravenously on day
npj Breast Cancer (2022) 18
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1 of each 21-day cycle for a total of 17 cycles or 1 year. Patients on the TH
arm received paclitaxel 80 mg/m2 intravenously weekly with concurrent
trastuzumab, with a loading dose of 4 mg/kg followed by 2 mg/kg
administered intravenously, once per week, for 12 weeks. After the
completion of 12 weeks of concurrent trastuzumab plus paclitaxel, patients
received 6 mg/kg trastuzumab intravenously every 21 days for 13 cycles.

Study procedures
For this exploratory study, the analysis population was deﬁned as all
patients who received any amount of protocol therapy. Assessment of
LVEF with echocardiography or multigated acquisition scanning was
required at baseline, 3 months, 6 months, 9 months, and 12 months.
Interruption of dosing with trastuzumab or T-DM1 was required if a
signiﬁcant asymptomatic decrease of LVEF occurred, here deﬁned as a
decrease in the ejection fraction of 10–15 percentage points from baseline
with an ejection fraction at least 1 percentage point below the lower limit
of normal or a decrease of 16 or more percentage points from baseline. If
the ejection fraction did not increase substantially and two consecutive
holds of therapy were required, the patient was withdrawn from study
treatment. Furthermore, diagnosis of grade 3–4 LVSD during protocol
therapy required cessation of trastuzumab therapy. For these patients, we
reported the registration date, protocol therapy starting date, offtreatment date, number of cycles administered, and LVEF percentages.
Patients who went off treatment early due to grade 3–4 LVSD were also
required to have follow-up LVEF assessments 3, 6, and 12 months after the
event. All patients with interval development of either symptomatic or
asymptomatic LVEF decline described above requiring interruption of
trastuzumab or T-DM1 underwent repeat LVEF assessment using the same
modality after an interval of 4 weeks. If the LVEF did not recover to a
“continue” category as deﬁned by study guidelines and if two consecutive
“holds” were required, then the patient would be withdrawn from study
treatment. The incidence of grade 3–4 LVSD are secondary endpoints and
are the objectives of this current analysis. For these patients, we
retrospectively abstracted their medical records searching for baseline
information about hypertension, diabetes mellitus, dyslipidemia, coronaropathy, and use of cardiac and antidiabetic medications.

Statistical considerations
The co-primary objectives of the ATEMPT study were to evaluate invasive
disease-free survival in patients receiving T-DM1 and to compare the
incidence of clinically relevant toxicities in patients treated with T-DM1
versus TH. These results were previously published.
We analyzed the incidence of grade 3–4 LVSD and signiﬁcant
asymptomatic LVEF decline (previously deﬁned) as binary outcomes. Rates
of LVSD and asymptomatic LVEF decline and 95% CIs were calculated
using the Wilson method. Time to cardiac dysfunction was assessed using
the methods of Kaplan–Meier. The association between risk factors and
cardiac dysfunction was assessed using risk ratios, associated 95% Wald
conﬁdence intervals, and the exact mid-p value. All analyses were
conducted using R v3.6.1.

Reporting Summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
Individual participant data that underlie the results reported in this article are not
able to be shared at this time as patients remain in study follow-up.

Received: 29 September 2021; Accepted: 14 January 2022;

REFERENCES
1. Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G. & Bartlett, J. M. Expression of the
HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200,
290–297 (2003).
2. Lovekin, C. et al. c-erbB-2 oncoprotein expression in primary and advanced breast
cancer. Br. J. Cancer 63, 439–443 (1991).

npj Breast Cancer (2022) 18

3. Burstein, H. J. The distinctive nature of HER2-positive breast cancers. N. Engl. J.
Med. 353, 1652–1654 (2005).
4. Pernas, S. & Tolaney, S. M. Management of early-stage human epidermal growth
factor receptor 2-positive breast cancer. JCO Oncol. Pr. 17, 320–330 (2021).
5. Gonzalez-Angulo, A. M. et al. High risk of recurrence for patients with breast
cancer who have human epidermal growth factor receptor 2-positive, nodenegative tumors 1 cm or smaller. J. Clin. Oncol. 27, 5700–5706 (2009).
6. Vaz-Luis, I. et al. Outcomes by tumor subtype and treatment pattern in women
with small, node-negative breast cancer: a multi-institutional study. J. Clin. Oncol.
32, 2142–2150 (2014).
7. Curigliano, G. et al. Clinical relevance of HER2 overexpression/ampliﬁcation in
patients with small tumor size and node-negative breast cancer. J. Clin. Oncol. 27,
5693–5699 (2009).
8. Chia, S. et al. Human epidermal growth factor receptor 2 overexpression as a
prognostic factor in a large tissue microarray series of node-negative breast
cancers. J. Clin. Oncol. 26, 5697–5704 (2008).
9. Barroso-Sousa, R., Exman, P. & Tolaney, S. M. De-escalating treatment in the
adjuvant setting in HER2-positive breast cancer. Future Oncol. 14, 937–945 (2018).
10. Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative,
HER2-positive breast cancer. N. Engl. J. Med. 372, 134–141 (2015).
11. Tolaney, S. M. et al. Seven-year follow-up analysis of adjuvant paclitaxel and
trastuzumab trial for node-negative, human epidermal growth factor receptor
2-positive breast cancer. J. Clin. Oncol. 37, 1868–1875 (2019).
12. Curigliano, G. et al. De-escalating and escalating treatments for early-stage breast
cancer: the St. Gallen International Expert Consensus Conference on the primary
therapy of early breast cancer 2017. Ann. Oncol. 28, 1700–1712 (2017).
13. NCCN. Breast cancer (Version 2.2019). https://www.nccn.org/professionals/
physician_gls/pdf/breast.pdf (2019).
14. Tolaney, S. M. et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a
randomized clinical trial. J. Clin. Oncol. 39, 2375–2385 (2021).
15. von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2positive breast cancer. N. Engl. J. Med. 380, 617–628 (2019).
16. de Azambuja, E. et al. A pooled analysis of the cardiac events in the trastuzumab
adjuvant trials. Breast Cancer Res. Treat. 179, 161–171 (2020).
17. Dempsey, N. et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk
factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed
therapies. Breast Cancer Res. Treat. 188, 21–36 (2021).
18. Dang, C. et al. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel
and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol. 2,
29–36 (2016).
19. Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J.
Med. 365, 1273–1283 (2011).
20. Jones, S. E. et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in
patients with HER2-ampliﬁed early stage breast cancer: a single-group, openlabel, phase 2 study. Lancet Oncol. 14, 1121–1128 (2013).
21. de Azambuja, E. et al. Trastuzumab-associated cardiac events at 8 years of
median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J. Clin. Oncol. 32,
2159–2165 (2014).
22. Romond, E. H. et al. Seven-year follow-up assessment of cardiac function in
NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide
followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for
patients with node-positive, human epidermal growth factor receptor 2-positive
breast cancer. J. Clin. Oncol. 30, 3792–3799 (2012).

ACKNOWLEDGEMENTS
Supported by Genentech and the Gloria Spivak Faculty Advancement Fund (Tolaney).
We are grateful for the funding support to the TBCRC from The Breast Cancer
Research Foundation and Susan G. Komen.

AUTHOR CONTRIBUTIONS
Conceptualization: R.B.-S., N.T., and S.M.T. Data curation: R.B.-S., M.D., N.T., and S.M.T.
Formal Analysis: N.T. Funding acquisition: S.M.T. Investigation: S.M.T., C.D., S.J.I., V.V.,
M.F., T.M., D.W., A.C.W., H.S.R., D.Z., L.H., V.K.G., F.B., A.M.G., K.M., N.T., B.A., R.N., M.R., V.
A., C.V.P., M.L., H.B., A.P., and I.K. Methodology: N.T. Supervision: S.M.T. Writing —
original draft: R.B.-S., P.T., and S.M.T. Writing—review and editing: all authors. First
authors: R.B.-S. Senior author: S.M.T.

COMPETING INTERESTS
Romualdo Barroso-Sousa: Consulting fees (e.g., advisory boards): AstraZeneca, Eli Lilly,
Libbs, Merck, Roche, Zodiac. Fees for non-CME services received directly from

Published in partnership with the Breast Cancer Research Foundation

R. Barroso-Sousa et al.

7
commercial interest or their Agents (e.g., speakers’ bureaus): Bard Access, BMS, Eli
Lilly, Libbs, Merck, Novartis, Pﬁzer, Roche. Research funding (to institution): Roche,
BMS. Travel/accommodation/expenses: Eli Lilly, Roche, Daichi Sankyo, Merck. Paolo
Tarantino: Consulting or advisory role: AstraZeneca. Chau Dang. Honoraria: Puma
Biotechnology, eviCore healthcare. Consulting or advisory role: Puma Biotechnology,
eviCore healthcare. Research funding: Genentech/Roche, Puma Biotechnology.
Denise Yardley. Consulting or advisory role: Novartis, Biotheranostics, Bristol Myers
Squibb, G1 Therapeutics, Athenex, Immunomedics, Sanoﬁ/Aventis, R-Pharm, Lilly.
Speakers’ Bureau: Novartis, Genentech/Roche, Genentech/Roche. Research funding:
Genentech/Roche, Novartis, MedImmune, Lilly, Medivation, Pﬁzer, Tesaro, Macrogenics, AbbVie, Merck, Clovis Oncology, Amgen, Biomarin, Biothera, Dana-Farber
Cancer Hospital, Incyte, Innocrin Pharma, Nektar, NSABP Foundation, Odonate
Therapeutics, Polyphor. Travel, accommodations, expenses: Novartis, Genentech/
Roche. Steven Isakoff. Consulting or advisory role: AbbVie, OncoPep, Puma
Biotechnology, Seattle Genetics, Novartis. Research funding: Genentech, PharmaMar,
AbbVie, OncoPep, Merck, AstraZeneca/MedImmune, Outcomes4Me. Vicente Valero.
Honoraria: Genentech/Roche, Merck, Novartis. Consulting or advisory role: Genentech/Roche, Novartis, Merck. Travel, accommodations, expenses: Genentech/Roche.
Therese Mulvey. Consulting or advisory role: Outcomes4Me. Ron Bose. Consulting or
advisory role: Genentech. Research funding: Puma Biotechnology. Antonio Wolff.
Consulting or advisory role: Ionis Pharmaceuticals. Research funding: Biomarin,
Celldex. Patents, Royalties, Other Intellectual Property: Antonio Wolff has been
named as an inventor on one or more issued patents or pending patent applications
related to methylation in breast cancer and has assigned his rights to JHU and
participates in a royalty sharing agreement with JHU. Open payments link: https://
openpaymentsdata.cms.gov/physician/357301/summary. Katherine Reeder-Hayes.
Research funding: Pﬁzer. Hope Rugo. Honoraria: Puma Biotechnology, Mylan.
Consulting or advisory role: Samsung. Research funding: Macrogenics, OBI Pharma,
Eisai, Pﬁzer, Novartis, Lilly, Genentech, Merck, Immunomedics, Odonate Therapeutics,
Daiichi Sankyo, Seattle Genetics, Sermonix Pharmaceuticals, AstraZeneca. Travel,
accommodations, expenses: Pﬁzer, Novartis, Macrogenics, Mylan, Daiichi Sankyo,
AstraZeneca Spain, Merck. Open payments link: https://openpaymentsdata.cms.gov/
summary. Bhuvaneswari Ramaswamy. Consulting or advisory role: Eisai. Lowell Hart.
Honoraria: Novartis, Daiichi Sankyo, AstraZeneca, Seattle Genetics, G1 Therapeutics,
Veracyte, Karyopharm Therapeutics. Consulting or advisory role: Genentech/Roche,
Amgen, G1 Therapeutics, Merck, Seattle Genetics. Speakers’ Bureau: Bristol Myers
Squibb, Lilly, Pﬁzer, Genentech, AstraZeneca, Novartis. Research funding: Novartis,
Genentech/Roche, Bristol Myers Squibb, G1 Therapeutics, Seattle Genetics. Vijayakrishna Gadi. Stock and other ownership interests: Sengine precision medicine, Novilla,
3rdEyeBio, New Equilibrium Biosciences, Phoenix Molecular Designs. Consulting or
advisory role: Seattle Genetics, Puma Biotechnology, Sanoﬁ, Hologics. Speakers’
Bureau: Seagen, Puma, Genentech/Roche. Research funding: Agendia (to institution).
Travel, accommodations, expenses: Puma, Seagen, Genentech/Roche. Open payments link: https://openpaymentsdata.cms.gov/physician/2511. Bryan Schneider.
Honoraria: Lilly, Research to Practice. Paul Marcom. Consulting or advisory role:
Genentech/Roche, Immunomedics. Research funding: Novartis, Genentech/Roche,
AstraZeneca, Verily, Glycomimetics, Millennium. Open payments link: https://
openpaymentsdata.cms.gov/physician/237508/summary. Kathy Albain. Consulting
or advisory role: Novartis, Pﬁzer, Myriad Genetics, Genomic Health, Agendia,
Genentech/Roche. Research funding: Seattle Genetics. Other relationship: Puma
Biotechnology. Nadine Tung. Research funding: AstraZeneca. Rita Nanda. Consulting
or advisory role: Merck, Genentech/Roche, Pﬁzer, Macrogenics, Daiichi Sankyo,
Athenex, Aduro Biotech, ION Pharma, Seattle Genetics, Immunomedics. Research
funding: Corcept Therapeutics, Celgene, Merck, Seattle Genetics, Genentech/Roche,
Odonate Therapeutics, Pﬁzer, AstraZeneca, AbbVie, Immunomedics. Other relationship: G1 Therapeutics. Rachel Jankowitz. Honoraria: Eisai. Consulting or advisory role:
Merck. Mothaffar Rimawi. Consulting or advisory role: Macrogenics, Daiichi Sankyo,
Seattle Genetics, Genentech. Research funding: Pﬁzer. Vandana Abramson. Employment: HCA Healthcare. Consulting or advisory role: Eisai, Daiichi Sankyo, Abbvie.
Research funding: Genentech/Roche, Lilly. Paula Pohlmann. Leadership: Immunonet
BioSciences. Stock and other ownership interests: Immunonet BioSciences. Honoraria:
Dava Oncology, OncLive/MJH Life Sciences, Frontiers—Publisher. Consulting or
advisory role: Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet
BioSciences, Pﬁzer, HERON, Puma Biotechnology, Sirtex Medical, Caris Life Sciences,
Juniper Pharmaceuticals, Bolt Biotherapeutics. Speakers’ Bureau: Genentech/Roche.
Research Funding: Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapeutics,
Caris Centers of Excellence, Pﬁzer, Pieris Pharmaceuticals, Cascadian Therapeutics,
Bolt Biotherapeutics, Byondis, Seagen. Patents, Royalties, Other Intellectual Property:

Published in partnership with the Breast Cancer Research Foundation

United States Patent no. 8486413, United States Patent no. 8501417, United States
Patent no. 9023362, United States Patent no. 9745377, Patent application. Catherine
Van Poznak. Research funding: Bayer. Patents, Royalties, Other Intellectual Property:
UpToDate. Andres Forero-Torres. Employment: Seattle Genetics. Stock and other
ownership interests: Seattle Genetics. Minetta Liu. Research funding: Eisai, Seattle
Genetics, Novartis, Roche/Genentech, GRAIL, Merck, Tesaro, Menarini Silicon
Biosystems, Genomic Health. Travel, accommodations, expenses: GRAIL, Merck,
Menarini Silicon Biosystems, Pﬁzer, Genomic Health, AstraZeneca, Ionis Pharmaceuticals. Kathryn Ruddy. Patents, Royalties, Other Intellectual Property: My husband is a
co-inventor of technology licensed by Mayo Clinic to AliveCor (MountainView, CA),
which makes a smartphone-enabled remote ECG monitoring system. Richard Gelber.
Research funding: AstraZeneca, Novartis, Roche, Merck, Pﬁzer. Travel, accommodations, expenses: Roche, AstraZeneca, Novartis. Bill Barry. Employment: Rho. Ann
Partridge. Patents, Royalties, Other Intellectual Property: I receive small royalty
payments for co-authoring the breast cancer survivorship section of UpToDate.
Travel, accommodations, expenses: Novartis. Eric Winer. Honoraria: Genentech/
Roche, Genomic Health. Consulting or advisory role: Leap Therapeutics, Seattle
Genetics, Jounce Therapeutics, GlaxoSmithKline, Carrick Therapeutics, Lilly, G1
Therapeutics, Syros Pharmaceuticals, Genentech/Roche, Gilead Sciences, Zymeworks,
Athenex. Research funding: Genentech. Other Relationship: InﬁniteMD. Ian Krop.
Employment: AMAG Pharmaceuticals, Freeline Therapeutics. Leadership: AMAG
Pharmaceuticals, Freeline Therapeutics. Stock and other ownership interests: AMAG
Pharmaceuticals, Freeline Therapeutics, Vertex. Honoraria: Genentech/Roche, AstraZeneca, Celltrion. Consulting or advisory role: Genentech/Roche, Seattle Genetics,
Daiichi Sankyo, Macrogenics, Taiho Pharmaceutical, Context Therapeutics, Novartis,
Merck, Ionis Pharmaceuticals, Bristol Myers Squibb, AstraZeneca. Research funding:
Genentech, Pﬁzer. Sara Tolaney. Consulting or advisory role: Novartis, Pﬁzer, Merck,
Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Genentech, Eisai, Sanoﬁ, Celldex, Bristol Myers Squibb, Paxman, Seattle Genetics, Odonate
Therapeutics, AbbVie, Silverback Therapeutics, G1 Therapeutics, OncoPep, Kyowa
Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex,
Immunomedics/Gilead, Mersana, Certara. Research funding: Genentech/Roche,
Merck, Exelixis, Pﬁzer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca,
NanoString Technologies, Cyclacel, Nektar, Immunomedics, Odonate Therapeutics,
Sanoﬁ, Seattle Genetics. Travel, accommodations, expenses: AstraZeneca, Lilly, Merck,
Nektar, Novartis, Pﬁzer, Genentech/Roche, Immunomedics, Eisai, NanoString Technologies, Puma Biotechnology, Celldex. No other potential conﬂicts of interest were
reported.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41523-022-00385-2.
Correspondence and requests for materials should be addressed to Sara M. Tolaney.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2022

npj Breast Cancer (2022) 18

